Skip to main content

Advertisement

SpringerLink
Log in

The Importance of Primary Care in Cardio-Oncology

  • Cardio-oncology (MG Fradley, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

There is significant interplay between cancer and cardiovascular disease involving shared risk factors, cross disease communication where cardiovascular events can influence cancer recurrence, and mortality rates and cardiotoxicity from cancer treatments with resultant increased cardiovascular mortality and morbidity in cancer patients. This is a major cause of death in many long-term cancer survivors. As a result, cardio-oncology, which involves the prevention, early detection, and optimal treatment of cardiovascular disease in patients treated for cancer, is expanding globally. However, there is still limited awareness of its importance and limited application of the lessons already learnt. Primary care physicians, and their clinical teams, especially nursing colleagues, have a foundation role in the management of all patients, and this paper outlines areas where they can lead in the cardio-oncology management of cancer patients. Although there is currently a lack of an adequate clinical framework or shared care plan, primary care physicians have a role to play in the various phases of cancer treatment: pre-therapy, during therapy, and survivorship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Wild CP. The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer. 2019;19(3):123–4.

    CAS  PubMed  Google Scholar 

  2. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.

    PubMed  Google Scholar 

  3. Suh M, Song S, Cho HN, Park B, Jun JK, Choi E, et al. Trends in participation rates for the national cancer screening program in Korea, 2002–2012. Cancer Res Treat. 2017;49(3):798–806.

    PubMed  Google Scholar 

  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  5. Cancer Survivorship: American Cancer Society; 2021. Available from: https://canceratlas.cancer.org/the-burden/cancer-survivorship/. Accessed 14 Apr 2021.

  6. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80.

    PubMed  PubMed Central  Google Scholar 

  7. Liu JE. Anthracycline-Induced Cardiotoxicity. JACC Cardiooncol. 2020;2(1):23–5.

    PubMed  PubMed Central  Google Scholar 

  8. Barish R, Gates E, Barac A. Trastuzumab-induced cardiomyopathy. Cardiol Clin. 2019;37(4):407–18.

    PubMed  Google Scholar 

  9. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.

    PubMed  PubMed Central  Google Scholar 

  10. Ryan CJ, Morgans AK. Addressing Cardiovascular Risk of prostate cancer hormonal therapy. JACC Cardiooncol. 2020;2(1):82–3.

    PubMed  PubMed Central  Google Scholar 

  11. Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293–303.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78.

    CAS  PubMed  Google Scholar 

  13. Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardiooncology. 2019;5:13.

    PubMed  PubMed Central  Google Scholar 

  14. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.

    PubMed  PubMed Central  Google Scholar 

  15. Bishnoi Rohit, Xie Zhigang, Shah Chintan, Bian Jiang, Murthy Hemant S, Wingard John R, Farhadfar Nosha. Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis. Cancer Med. 2020;10(1):70–8. https://doi.org/10.1002/cam4.3568.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.

    Google Scholar 

  18. Koczwara B, Meng R, Miller MD, Clark RA, Kaambwa B, Marin T, et al. Late mortality in people with cancer: a population‐based Australian study. Med J Aust. 2020;214(7):318–23. https://doi.org/10.5694/mja2.50879Showing the importance of cardiovascular disease as a competing cause of death in long term cancer survivors.

    Article  PubMed  Google Scholar 

  19. Ye Y, Otahal P, Marwick TH, Wills KE, Neil AL, Venn AJ. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: an Australian population-based study. Cancer. 2019;125(3):442–52.

    PubMed  Google Scholar 

  20. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97.

    PubMed  PubMed Central  Google Scholar 

  21. Untaru R, Chen D, Kelly C, May A, Collins NJ, Leitch J, et al. Suboptimal Use of cardioprotective medications in patients with a history of cancer. JACC Cardiooncol. 2020;2(2):312–5.

    PubMed  PubMed Central  Google Scholar 

  22. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–66.

    PubMed  PubMed Central  Google Scholar 

  23. World Health Organisation. Cancer. 2020. Available from: https://www.who.int/health-topics/cancer#tab=tab_2. Accessed 14 Apr 2021.

  24. Labarthe D, Lloyd-Jones DM. 50x50x50: Cardiovascular health and the cardiovascular disease endgame. Circulation. 2018;138(10):968–70.

    PubMed  Google Scholar 

  25. Gapstur SM, Drope JM, Jacobs EJ, Teras LR, McCullough ML, Douglas CE, et al. A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. CA Cancer J Clin. 2018;68(6):446–70.

    PubMed  Google Scholar 

  26. Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med. 2020;26(9):1452–8 In an elegant mouse model and then showing clinical relevance with human data this paper shows that there is cross disease communication between myocardial infarction and cancer.

    PubMed  PubMed Central  Google Scholar 

  27. Hayek SS, Ganatra S, Lenneman C, Scherrer-Crosbie M, Leja M, Lenihan DJ, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. J Am Coll Cardiol. 2019;73(17):2226–35.

    PubMed  PubMed Central  Google Scholar 

  28. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular Health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–46.

    PubMed  PubMed Central  Google Scholar 

  29. Desai MY, Windecker S, Lancellotti P, Bax JJ, Griffin BP, Cahlon O, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74(7):905–27.

    PubMed  Google Scholar 

  30. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911.

    PubMed  Google Scholar 

  31. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.

    PubMed  Google Scholar 

  32. Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016;32(7):831–41.

    PubMed  Google Scholar 

  33. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;(11):1945–1960. https://doi.org/10.1002/ejhf.1920.

  34. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90 An international panel of experts provide a pragmatic approach to cardiac surveillance in cancer patients under the auspices of ESMO.

    CAS  PubMed  Google Scholar 

  35. Iliescu C, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). Catheter Cardiovasc Interv. 2016;87(5):895–9.

    PubMed  Google Scholar 

  36. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Peng J, Rushton M, Johnson C, Brezden-Masley C, Sulpher J, Chiu MG, et al. An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments. Cardiooncology. 2019;5:12 An insight into the lack of appreciation of the importance of CardioOncology in cancer care providers.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Chung IY, Lee JW, Moon HG, Shin KH, Han W, Son BH, et al. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study. Breast. 2020;53:125–9 This paper adds to the evidence of anthracycline cardiotoxicity potential at standard low doses and the potential for late manifestation of cardiotoxicity.

    PubMed  PubMed Central  Google Scholar 

  39. Cardinale D, Sandri MT, Martinoni A, Tricca LabTech A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517–22.

    CAS  PubMed  Google Scholar 

  40. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.

    CAS  PubMed  Google Scholar 

  41. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595–603.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Azizova TV, Muirhead CR, Druzhinina MB, Grigoryeva ES, Vlasenko EV, Sumina MV, et al. Cardiovascular diseases in the cohort of workers first employed at Mayak PA in 1948–1958. Radiat Res. 2010;174(2):155–68.

    CAS  PubMed  Google Scholar 

  43. Shimizu Y, Kodama K, Nishi N, Kasagi F, Suyama A, Soda M, et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950–2003. BMJ. 2010;340:b5349.

    PubMed  PubMed Central  Google Scholar 

  44. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–43.

    PubMed  Google Scholar 

  45. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    CAS  PubMed  Google Scholar 

  46. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, Aleman BM. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4):djv008. https://doi.org/10.1093/jnci/djv008.

  47. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

    CAS  PubMed  Google Scholar 

  48. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016;57(5):439–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502.

    CAS  PubMed  Google Scholar 

  51. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.

    PubMed  Google Scholar 

  52. Dent SF, Kikuchi R, Kondapalli L, Ismail-Khan R, Brezden-Masley C, Barac A, et al. Optimizing cardiovascular health in patients with cancer: a practical review of risk assessment, monitoring, and prevention of cancer treatment–related cardiovascular toxicity. Am Soc Clin Oncol Educ Book. 2020;40:501–15.

    Google Scholar 

  53. Brown S-A, Ray JC, Herrmann J. Precision cardio-oncology: a systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors. J Cardiovasc Transl Res. 2020;13(3):402–16.

    PubMed  Google Scholar 

  54. Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59(7):1554–64.

    CAS  PubMed  Google Scholar 

  55. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.

    PubMed  PubMed Central  Google Scholar 

  56. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.

    PubMed  PubMed Central  Google Scholar 

  57. Lenneman CG, Sawyer DB. Cardio-Oncology: An update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008–20.

    CAS  PubMed  Google Scholar 

  58. Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021;22(6):47.

    PubMed  PubMed Central  Google Scholar 

  59. Hu J-R, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40(3):e55–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Wu P, Oren O, Gertz MA, Yang EH. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66.

    PubMed  Google Scholar 

  62. Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging. 2018;11(8):1132–49.

    PubMed  Google Scholar 

  63. Sylvester CB, Abe JI, Patel ZS, Grande-Allen KJ. Radiation-induced cardiovascular disease: mechanisms and importance of linear energy transfer. Front Cardiovasc Med. 2018;5:5.

    PubMed  PubMed Central  Google Scholar 

  64. Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS. Association of Primary Care Physician Supply With Population Mortality in the United States, 2005–2015. JAMA Intern Med. 2019;179(4):506–14.

    PubMed  PubMed Central  Google Scholar 

  65. Yang W, Williams JH, Hogan PF, Bruinooge SS, Rodriguez GI, Kosty MP, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. J Oncol Pract. 2014;10(1):39–45.

    PubMed  Google Scholar 

  66. Lawrence RA, McLoone JK, Wakefield CE, Cohn RJ. Primary care physicians’ perspectives of their role in cancer care: a systematic review. J Gen Intern Med. 2016;31(10):1222–36.

    PubMed  PubMed Central  Google Scholar 

  67. Felicetti F, Fortunati N, Brignardello E. Cancer survivors: An expanding population with an increased cardiometabolic risk. Diabetes Res Clin Pract. 2018;143:432–42.

    PubMed  Google Scholar 

  68. Simon MS, Beebe-Dimmer JL, Hastert TA, Manson JE, Cespedes Feliciano EM, Neuhouser ML, et al. Cardiometabolic risk factors and survival after breast cancer in the Women’s Health Initiative. Cancer. 2018;124(8):1798–807.

    CAS  PubMed  Google Scholar 

  69. Brown SA. Preventive cardio-oncology: the time has come. Front Cardiovasc Med. 2019;6:187.

    PubMed  Google Scholar 

  70. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890.

    PubMed  PubMed Central  Google Scholar 

  71. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91.

    PubMed  PubMed Central  Google Scholar 

  72. Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020;141(7):549–59.

    PubMed  Google Scholar 

  73. Melloni C, Nelson A. Effect of androgen deprivation therapy on metabolic complications and cardiovascular risk. J Cardiovasc Transl Res. 2020;13(3):451–62.

    PubMed  Google Scholar 

  74. Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14e000082. https://doi.org/10.1161/HCG0000000000000082

  75. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73(24):3153–67.

    PubMed  Google Scholar 

  76. Venkataraman P, Stanton T, Liew D, Huynh Q, Nicholls SJ, Mitchell GK, et al. Coronary artery calcium scoring in cardiovascular risk assessment of people with family histories of early onset coronary artery disease. Med J Aust. 2020;213(4):170–7. https://doi.org/10.5694/mja2.50702.

    Article  PubMed  Google Scholar 

  77. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Silverman MG, Blaha MJ, Krumholz HM, Budoff MJ, Blankstein R, Sibley CT, et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2014;35(33):2232–41.

    CAS  PubMed  Google Scholar 

  79. Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J Am Coll Cardiol. 2018;72(25):3233–42 This paper demonstrates the benefit of using coronary artery calcium scoring to assist in lipid treatment decisions.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Xie X, Zhao Y, de Bock GH, de Jong PA, Mali WP, Oudkerk M, et al. Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging. 2013;6(4):514–21.

    PubMed  Google Scholar 

  81. Williams MC, Abbas A, Tirr E, Alam S, Nicol E, Shambrook J, et al. Reporting incidental coronary, aortic valve and cardiac calcification on non-gated thoracic computed tomography, a consensus statement from the BSCI/BSCCT and BSTI. Br J Radiol. 2021;94(1117):20200894. https://doi.org/10.1259/bjr.20200894 Recommendations from imaging bodies on the reporting of incidental findings of coronary artery calcification.

    Article  PubMed  Google Scholar 

  82. Ligibel JA, Denlinger CS. New NCCN guidelines for survivorship care. J Natl Compr Canc Netw. 2013;11(5 Suppl):640–4.

    PubMed  Google Scholar 

  83. Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, McCarthy AL, Murnane A, Patchell S, Adams D. Clinical Oncology Society of Australia position statement on exercise in cancer care. Medical Journal of Australia 2018;209:184–187. https://doi.org/10.5694/mja18.00199.

  84. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.

    PubMed  Google Scholar 

  85. Fuller JT, Hartland MC, Maloney LT, Davison K. Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br J Sports Med. 2018;52(20):1311.

    PubMed  Google Scholar 

  86. Grassi L, Spiegel D, Riba M. Advancing psychosocial care in cancer patients. F1000Res. 2017;6:2083.

    PubMed  PubMed Central  Google Scholar 

  87. Bultz BD, Cummings GG, Grassi L, Travado L, Hoekstra-Weebers J, Watson M. 2013 President’s Plenary International Psycho-oncology Society: embracing the IPOS standards as a means of enhancing comprehensive cancer care. Psychooncology. 2014;23(9):1073–8.

    CAS  PubMed  Google Scholar 

  88. Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, et al. The expanding role of primary care in cancer control. Lancet Oncol. 2015;16(12):1231–72.

    PubMed  Google Scholar 

  89. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51(13):1237–46.

    PubMed  PubMed Central  Google Scholar 

  90. Wirtz PH, von Kanel R. Psychological stress, inflammation, and coronary heart disease. Curr Cardiol Rep. 2017;19(11):111.

    PubMed  Google Scholar 

  91. Pollack LA, Adamache W, Ryerson AB, Eheman CR, Richardson LC. Care of long-term cancer survivors: physicians seen by Medicare enrollees surviving longer than 5 years. Cancer. 2009;115(22):5284–95.

    PubMed  Google Scholar 

  92. Rokitka DA, Curtin C, Heffler JE, Zevon MA, Attwood K, Mahoney MC. Patterns of loss to follow-up care among childhood cancer survivors. J Adolesc Young Adult Oncol. 2017;6(1):67–73.

    PubMed  PubMed Central  Google Scholar 

  93. Jefford M, Koczwara B, Emery J, Thornton-Benko E, Vardy JL. The important role of general practice in the care of cancer survivors. Aust J Gen Pract. 2020;49(5):288–92.

    PubMed  Google Scholar 

  94. Cajita MI, Cajita TR, Han HR. Health Literacy and Heart Failure: A Systematic Review. J Cardiovasc Nurs. 2016;31(2):121–30.

    PubMed  PubMed Central  Google Scholar 

  95. Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2018;124(4):850–7.

    CAS  PubMed  Google Scholar 

  96. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021 Mar;23(3):352–380. https://doi.org/10.1002/ejhf.2115.

  97. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.

    CAS  PubMed  Google Scholar 

  98. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.

    PubMed  Google Scholar 

  99. Runciman WB, Hunt TD, Hannaford NA, Hibbert PD, Westbrook JI, Coiera EW, et al. CareTrack: assessing the appropriateness of health care delivery in Australia. Med J Aust. 2012;197(2):100–5.

    PubMed  Google Scholar 

  100. Visser A, van de Ven EM, Ruczynski LI, Blaisse RJ, van Halteren HK, Aben K, et al. Cardiac monitoring during adjuvant trastuzumab therapy: guideline adherence in clinical practice. Acta Oncol. 2016;55(4):423–9.

    PubMed  Google Scholar 

Download references

Funding

This work is supported in part by National Heart Foundation (101918) (Aaron L Sverdlov), National Heart Foundation (104814) (Doan TM Ngo), NSW Ministry of Health (Cardiovascular Capacity Building Program) (Aaron L Sverdlov), NSW Ministry of Health (EMCR Fellowship) (Doan TM Ngo), Hunter Cancer Research Alliance (New Strategic Initiatives Grant) (Aaron L Sverdlov), Hunter Cancer Research Alliance (New Strategic Initiatives Grant) (Doan TM Ngo), John Hunter Charitable Trust (Project Grant) (Aaron L Sverdlov), and John Hunter Charitable Trust (Project Grant) (Doan TM Ngo).

Author information

Authors and Affiliations

  1. GenesisCare Cardiology, GenesisCare, Building 1 & 11, The Mill, 41-43 Bourke Road, Alexandria, Sydney, NSW, 2015, Australia

    Daniel A. Cehic MBBS, MBA, GAICD, FCSANZ, FRACP

  2. Discipline of Medicine, School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, 5000, Australia

    Daniel A. Cehic MBBS, MBA, GAICD, FCSANZ, FRACP

  3. College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, 2308, Australia

    Aaron L. Sverdlov MBBS, PhD, FRACP, FESC, FACC

  4. Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia

    Aaron L. Sverdlov MBBS, PhD, FRACP, FESC, FACC

  5. Hunter Cancer Research Alliance, Waratah, NSW, 2298, Australia

    Aaron L. Sverdlov MBBS, PhD, FRACP, FESC, FACC & Doan T. M. Ngo B.Pharm, B. Health Sci (Hons), PhD, FESC, FCSANZ

  6. Hunter New England Local Health District, Newcastle, NSW, 2305, Australia

    Aaron L. Sverdlov MBBS, PhD, FRACP, FESC, FACC & Doan T. M. Ngo B.Pharm, B. Health Sci (Hons), PhD, FESC, FCSANZ

  7. Department of Medical Oncology, Flinders Medical Centre, Flinders Drive, Bedford Park, SA, 5042, Australia

    Bogda Koczwara AM, BM, BS, FRACP, MBioethics, FAICD

  8. Flinders Health and Medical Research Institute, Flinders University, Flinders Drive, Bedford Park, SA, 5042, Australia

    Bogda Koczwara AM, BM, BS, FRACP, MBioethics, FAICD

  9. Department of General Practice and Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Level 10, Victorian Comprehensive Cancer Centre, 305 Grattan St, Victoria, 3000, Australia

    Jon Emery MA, MBBCh, MRCGP, FRACGP, DPhil

  10. School of Biomedical Science and Pharmacy, Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia

    Doan T. M. Ngo B.Pharm, B. Health Sci (Hons), PhD, FESC, FCSANZ

  11. Bondi Road Doctors, 27 Bondi Road, Bondi Junction, Sydney, NSW, 2022, Australia

    Elysia Thornton-Benko BSc MBBS(Hons), PhD FRACGP

  12. Faculty of Medicine, Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children’s Hospital, University of NSW, Randwick, NSW, Australia

    Elysia Thornton-Benko BSc MBBS(Hons), PhD FRACGP

Authors
  1. Daniel A. Cehic MBBS, MBA, GAICD, FCSANZ, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron L. Sverdlov MBBS, PhD, FRACP, FESC, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bogda Koczwara AM, BM, BS, FRACP, MBioethics, FAICD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jon Emery MA, MBBCh, MRCGP, FRACGP, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Doan T. M. Ngo B.Pharm, B. Health Sci (Hons), PhD, FESC, FCSANZ
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elysia Thornton-Benko BSc MBBS(Hons), PhD FRACGP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel A. Cehic MBBS, MBA, GAICD, FCSANZ, FRACP.

Ethics declarations

Conflict of Interest

Daniel A. Cehic has recently received speaker fees from Menarini Australia Pty Ltd. Aaron L. Sverdlov has received a conference sponsorship grant from Bristol-Myers Squibb Australia Pty Ltd, an unrestricted educational grant from Celgene Pty Ltd, and an equipment loan for research support from Roche Diagnostics Pty Ltd. Bogda Koczwara declares that she has no conflict of interest. Jon Emery declares that he has no conflict of interest. Doan T.M. Ngo declares that she has no conflict of interest. Elysia Thornton-Benko declares that she has no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cehic, D.A., Sverdlov, A.L., Koczwara, B. et al. The Importance of Primary Care in Cardio-Oncology. Curr. Treat. Options in Oncol. 22, 107 (2021). https://doi.org/10.1007/s11864-021-00908-2

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00908-2

Keywords

Search

Navigation